The safety of treatments for angioedema with hereditary C1 inhibitor deficiency

Expert Opinion on Drug Safety

Volumn 14, Issue 11, 2015, Pages 1725-1736

  Zanichelli, Andrea ^a   Wu, Maddalena Alessandra ^a   Andreoli, Arnaldo ^a   Mansi, Marta ^a   Cicardi, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

androgens; angioedema; C1 inhibitor; ecallantide; icatibant; tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ICATIBANT; STANOZOLOL; TRANEXAMIC ACID; BRADYKININ;

ACNE; ANDROGEN THERAPY; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ARTERIAL WALL THICKNESS; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CENTRAL RETINA VEIN OCCLUSION; COMPLEMENT COMPONENT C1S INHIBITOR DEFICIENCY; COMPLEMENT DEFICIENCY; CONTROLLED CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; CYSTITIS; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; FATIGUE; HEADACHE; HEART INFARCTION; HEMATURIA; HEMORRHAGIC CYSTITIS; HIRSUTISM; HOME CARE; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; IMMUNOGENICITY; LIVER ADENOMA; LIVER TOXICITY; LONG TERM CARE; MENSTRUAL IRREGULARITY; MOOD CHANGE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RHABDOMYOLYSIS; SELF CARE; SHORT COURSE THERAPY; STOMACH DISEASE; SYSTEMATIC REVIEW (TOPIC); THROMBOGENICITY; THROMBOSIS; VEIN THROMBOSIS; VIRILIZATION; VOMITING; WEIGHT GAIN; ABDOMINAL PAIN; ANGIOEDEMAS, HEREDITARY; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; TIME FACTOR;

ABDOMINAL PAIN; ANGIOEDEMAS, HEREDITARY; ANIMALS; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; TIME FACTORS;

EID: 84947491230     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1094053     Document Type: Review

References (109)

1. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the hereditary angioedema international working group. Allergy 2014;69:602-16
2. Agostoni A, Aygoren-Pürsün E, Binkley KE, et al. Hereditary and acquired angiooedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114:S51-131
3. Zanichelli A, Arcoleo F, Barca M, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis 2015;10-11
4. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002;347:621-2
5. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009;15:69-78
6. Loghurst H, Cicardi M. Hereditary angio-edema. Lancet 2012;379:474-81
7. Wu MA, Zanichelli A, Mansi M, et al. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency. Expert Opin Pharmacother 2013;14(5):571-86
8. Cicardi M, Mannucci PM, Castelli R, et al. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate.Transfusion. 1995;35:209-12
9. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: A review. Transfus Apher Sci 2003;29:247-54
10. Lyseng-Williamson KA. Nanofiltered human C1 inhibitor concentrate (Cinryze): in hereditary angioedema. BioDrugs 2011;25:317-27
11. Bork K. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy 2014;6:533-51
12. EMEA. CPMP/BWP/269/95 rev. 3-Note for guidance on plasma-derived medicinal products. January 25, 2001; EMA
13. EMA/CHMP/BWP/706271/2010-Guideline on plasma-derived medicinal products. July 21, 2011
14. FDA. Code of Federal Regulations Title 29pè', Volume 7, Part 640.Additional standards for human blood and blood products. April 1, 2011
15. Groner A, Nowak T, Schäfer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012;52:2104-12
16. Tateishi J, Kitamoto T, Mohri S, et al. Scrapie removal using Planova virus removal filters. Biologicals 2001;29:17-25
17. Diez JM, Caballero S, Belda F, et al. Capacity of the manufacturing process of Flebogamma DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent. Biologicals 2010;38:670-4
18. World Health Organization. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of blood plasma products. 2004. p. 151-224
19. National Hemophilia Foundation. MASAC Recommendation regarding the use of recombinant clotting factor products with respect to pathogen transmission. 2014 [Last accessed 26 January 2015]
20. Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014;12:575-98
21. Federal Drugs Administration. SOP 420 2013
22. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010K;126:821-7e814
23. Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 2014;112:163-169e161
24. Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: A North American open-label study. Ann Allergy Asthma Immunol 2013;110:295-9
25. Arzneimittelkommission der deutschen rzteschaft: Schwerwiegende Thrombenbildung nach Berinert HS. Dtsch Arztebl International 2000;97:A-1016
26. Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012;125(9):938e1-7
27. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012;32:902-9
28. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guidelines. Allergy Asthma Clin Immunol 2014;10:50
29. Reshef A, Zanichelli A, Longhurst H, et al. Elevated D-Dimers in Attacks of Hereditary Angioedema Are Not Associated with Increased Thrombotic Risk. Allergy 2015;70(5):506-13
30. Craig TJ, Bewtra AK, Hurewitz D, et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc 2012;33:354-61
31. Cicardi M, Lorenza C. Zingale, Andrea Zanchelli. A patient with hereditary angioedema who experienced anaphylaxis in response to C1 esterase inhibitor is successfully treated with DX-88 (Ecallantide), a potent human plasma kallikrein inhibitor: A case study. Mol Immunol 2007;44:160-1
32. Hack CE, Mannesse M, Baboeram A, et al. Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. BioDrugs 2012;26:303-13
33. Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012;42:929-35
34. Li HH, Moldovan D, Bernstein JA, et al. Recombinant Human-C1 Inhibitor is Effective and Safe for Repeat Hereditary Angioedema Attacks. J Allergy Clin Immunol Pract 2015;3(3):417-23
35. Hack CE, Relan A, Baboeram A, et al. Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of IgE antibodies. Clin Drug Investig 2013;33:275-81
36. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41
37. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial. Ann Allergy Asthma Immunol 2011;107:529-37
38. CHMP assessment report for Firazyr. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency. 2008.Available from: www.emea.europa. eu/humandocs/PDFs/EPAR/firazyr/H-899-eu6.pdf
39. Baş M, Greve J, Hoffmann TK, et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013;68:1452-9
40. Aberer W, Maurer M, Reshef A, et al. Open-label, multicenter study of selfadministered icatibant for attacks of hereditary angioedema. Allergy 2014;69:305-14
41. Malbrán A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol 2014;177:544-53
42. Firazyr (icatibant), summary of product characteristics. Shire plc., St Helier, Jersey
43. Yao Y, Sheng Z, Li Y, et al. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther 2012;23:859-70
44. Kränkel N, Kuschnerus K, Müller M, et al. Novel insights into the critical role of bradykinin and the kinin B2 receptor for vascular recruitment of circulating endothelial repair-promoting mononuclear cell subsets: alterations in patients with coronary disease. Circulation 2013;127:594-603
45. Thornton E, Ziebell JM, Leonard AV, Vink R. Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury. Molecules 2010;15:6598-618
46. Gob E, Reymann S, Langhauser F, et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann Neurol 2015;77:784-803
47. Danielisova V, Gottlieb M, Bonova P, et al. Bradykinin postconditioning ameliorates focal cerebral ischemia in the rat. Neurochem Int 2014;72:22-9
48. Bovenzi V, Savard M, Morin J, et al. Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli. J Cell Physiol 2010;222:168-76
49. Kalbitor (ecallantide), package insert. Dyax Corp., MA, USA
50. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:523-9
51. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363:523-31
52. Sheffer AL, Campion M, Levy RJ, et al. Ecallantide(DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double blind, Phase 3 studies. J Allergy Clin Immunol 2011;128:153-159e4
53. Craig TJ, Li HH, Riedl M, et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract 2015;3:206-12e4
54. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67(2):147-57
55. Berinert (C1 esterase inhibitor, human) [summary of product characteristics]. CSL Behring
56. Cinryze (C1 esterase inhibitor [human]) [summary of product characteristics]. ViroPharma, Incorporated
57. Ruconest (conestat alfa) [summary of product characteristics]. Leiden, The Netherlands. Pharming Group NV
58. Levi M, Choi G, Picavet CJ, et al. Selfadministration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. Allergy Clin Immunol 2006;117(4):904-8
59. Hernández Fernandez de Rojas D, Ibanez E, Longhurst H, et al. Treatment of HAE attacks in the icatibant outcome survey: an analysis of icatibant selfadministration versus administration by health care professionals. Int Arch Allergy Immunol 2015;167(1):21-8
60. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99:194e196
61. Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: Safety of longterm stanozolol therapy. J Allergy Clin Immunol 2007;120:654-8
62. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: A long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153-61
63. Riedl MA. Critical appraisal of androgen use in hereditary angioedema: A systematic review. Ann Allergy Asthma Immunol 2015;114:281-8e287
64. Hosea SW, Santaella ML, Brown EJ, et al. Long term therapy of hereditary angioedema with danazol. Ann Intern Med 1980;93:809e812
65. Zurlo JJ, Frank MM. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril 1990;54:64-72
66. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981;68:181e187
67. Cicardi M, Bergamaschini L, Cugno M, et al. Long-term treatment of hereditary angioedema with attenuated androgens: A survey of a 13-year experience. J Allergy Clin Immunol 1991;87:768e773
68. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99:194e196
69. Szeplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005;115:864e869
70. Birjmohun RS, Kees Hovingh G, Stroes ES, et al. Effects of short-term and longterm danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema. Clin Ther 2008;30:2314e2323
71. Szegedi R, Szeplaki G, Varga L, et al. Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients. Atherosclerosis 2008;198:184-91
72. Farkas H, Czaller I, Csuka D, et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-A longitudinal study. Eur J Clin Pharmacol 2010;66:419-26
73. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002;36:707-9
74. Crampon D, Barnoud R, Durand M, et al. Danazol therapy: an unusual aetiology of hepatocellular carcinoma [letter]. J Hepatol 1998;29:1035-6
75. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angiooedema. Lancet 1999;353:1066e1067
76. Thoufeeq MH, Ishtiaq J, Abuzakouk M. Danazol-induced hepatocellular carcinoma in a patient with hereditary angioedema. J Gastrointest Cancer 2012;43(Suppl 1):S280eS282
77. Rahal S, Gilabert M, Ries P, et al. Hepatocellular carcinoma in a noncirrhotic liver after long-term use of danazol for hereditary angioedema. Case Rep Oncol 2014;7:825-7
78. Pedrosa M, Caballero T, Gómez-Traseira C, et al. Usefulness of abdominal ultrasonography in the follow-up of patients with hereditary C1-inhibitor deficiency. Ann Allergy Asthma Immunol 2009;102:483e486
79. Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983;72:294e298
80. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004;114:629-37
81. Santaella ML, Martinó A. Hereditary and acquired angioedema: experience with patients in Puerto Rico. P R Health Sci J 2004;23:13e18
82. Andriole GL, Brickman C, Lack EE, et al. Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema. J Urol 1986;1351:44e46
83. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972;286:808-12
84. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972;287:452-4
85. Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med 1992;120:129-39
86. Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditary C1inhibitor deficiency: A 21-month prospective study in a cohort of 103 patients. Allergy 2011;66:192-6
87. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol 2014;10:50
88. Zanichelli A, Mansi M, Periti G, Cicardi M. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency. Expert Rev Clin Immunol 2013;9:477-88
89. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24
90. Dunn CJ, Goa KL. Tranexamic acid: A review of its use in surgery and other indications. Drugs 1999;57:1005-32
91. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001;86:714-15
92. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993;70:238-40
93. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886
94. Uozaki Y, Watanabe G, Kotou K, et al. Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass. Jpn J Thorac Cardiovasc Surg 2001;49:273-8
95. Günaldi M, Helvaci A, Yildirim ND, et al. Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation. Cardiol J 2009;16:458-61
96. Sundstrom A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: A case-control study using the General Practice Research Database. BJOG 2009;116:91-7
97. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129:308-20
98. Sanhueza PI. Contraception in hereditary angioedema. Fertil Steril 2008;90:2015e21-2
99. McGlinchey PG, McCluskey DR. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci 2000;320:212-13
100. ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update 2009;15:265-77
101. Baker J, Riedl M, Banerji A, et al. Treatment or prophylaxis of acute attacks of hereditary angioedema (HAE) in pregnant subjects Poster 2312. WAO International Scientific Conference; 5-8 December 2010; Dubai, UAE
102. Baker JW, Craig TJ, Riedl MA, et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy Asthma Proc 2013;34(2):162-9
103. Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand 1970;49:241-2
104. Gorman PJ. Hereditary angioedema and pregnancy: A successful outcome using C1 esterase inhibitor concentrate. Can Fam Physician 2008;54:365-6
105. Lumry W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 2013;162:1017-22
106. Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012;52:100-7
107. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124:801-8
108. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22
109. Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007;120:e713-22